UBS China Healthcare 2026 Outlook: Opportunities in Global Expansion and Online Penetration
Summaries are public. PDF access requires an active membership; all members have the same access. Sign in
UBS views China's healthcare sector fundamentals as stable and improving, with innovation and globalization emerging as the most prominent themes. Biotechnology is the preferred subsector. After a 65% rebound in the HSBIO index and a 12% gain in the SW Pharmaceutical index during 2025—the first annual increase in four years—supportive macroeconomic policies and the expanding global footprints of industry leaders drove the recovery. A fourth-quarter pullback has created ample room for 2026 growth.
Top picks include BeOne, WuXi XDC, JD Health, and Hansoh Pharma. The CRO segment is expected to benefit from robust Chinese biopharma funding, which surged 87% year-over-year in 2025, alongside the strongest global financing quarter since the first quarter of 2022. Online pharmacies remain favored due to accelerating digital penetration in pharmaceutical sales.
Despite persistent pressures from medical insurance cost controls, such as Volume-Based Procurement and DRG/DIP reforms, alongside weak consumer sentiment, supportive policy implementation and optimized procurement measures should facilitate a recovery for leading companies. Overseas markets continue to serve as the primary growth engine for biopharmaceuticals and select medical devices, with outbound licensing deal volumes reaching record highs. Investors will likely focus on the execution of licensed assets and the sustainability of pipelines. The implementation uncertainty surrounding the Biosecure Act remains a key factor for CROs.